Difference between revisions of "Pomalidomide (Pomalyst)"
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
m |
||
| Line 5: | Line 5: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Toxicity management== | ||
*Use of Pomalidomide (Pomalyst) requires participation in the [http://celgeneriskmanagement.com Pomalyst REMS program] | *Use of Pomalidomide (Pomalyst) requires participation in the [http://celgeneriskmanagement.com Pomalyst REMS program] | ||
| − | + | ==Diseases for which it is established== | |
| + | *[[Multiple myeloma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Kaposi sarcoma]] | *[[Kaposi sarcoma]] | ||
*[[Light-chain (AL) amyloidosis]] | *[[Light-chain (AL) amyloidosis]] | ||
| − | |||
*[[Myelofibrosis]] | *[[Myelofibrosis]] | ||
Revision as of 01:33, 20 May 2022
General information
Class/mechanism: Second-generation immunomodulatory drug (IMiD)--a thalidomide analogue--with antineoplastic activity. Pomalidomide has been shown to inhibit growth and induce apoptosis of hematopoietic tumor cells, enhance natural killer (NK) and T-cell cell-mediated immunity, and suppress monocyte production of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Toxicity management
- Use of Pomalidomide (Pomalyst) requires participation in the Pomalyst REMS program
Diseases for which it is established
Diseases for which it is used
Patient drug information
- Pomalidomide (Pomalyst) package insert[1]
- Pomalidomide (Pomalyst) patient drug information (Chemocare)[4]
- Pomalidomide (Pomalyst) patient drug information (UpToDate)[5]
History of changes in FDA indication
Kaposi sarcoma
- 5/14/2020: Accelerated approval for adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy. (New disease entity with prior treatment requirement; based on NCI 12-C-0047)
- 5/14/2020: Accelerated approval for Kaposi sarcoma in adult patients who are HIV-negative. (New disease entity; based on NCI 12-C-0047)
Multiple myeloma
- 2/8/2013: Accelerated approval for treatment of multiple myeloma in patients who received at least two previous therapies including Lenalidomide (Revlimid) and Bortezomib (Velcade) who have progressive disease within 60 days of the completion of the last therapy. (Based on NIMBUS & CC-4047-MM-002)
- 4/23/2015: Converted to regular approval.
Also known as
- Code names: CC4047, CC-4047
- Generic name: 3-amino-thalidomide
- Brand names: Actimid, Ibipolid, Imnovid, Pomalid, Pomalyst